← Back to patent-cliff list
Tulobuterol
Tier C — Watch / tradeTulobuterol
Hokuriku Seiyaku Co Ltd
Originator
1998
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB2
Brand：Hokunalin
Indications (approved)：Acute respiratory distress syndrome, 肺气肿, Acute bronchitis, Chronic bronchitis, Asthma
Regional status
US
-
EU
-
China
Approved
2006-11-22
Japan
Approved
1998-09-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tulobuterol?
Approved indications include: Acute respiratory distress syndrome, 肺气肿, Acute bronchitis, Chronic bronchitis, Asthma.
When does the Tulobuterol patent expire?
No public expiry year is available for Tulobuterol yet; this page updates once verified.
How do I get a quote for Tulobuterol intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27